Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
284
Recruiting, any sponsor type, condition "anemia"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting284
- Completed1,821
284 trials
Showing 1 to 25, recently updated first.
National Cancer Institute (NCI)NIH
NCT06303193 · 160 participants (planned) · Start Nov 25, 2026 · Primary completion Jan 1, 2030
Drug: pacritinib · For: Myelodysplastic Syndromes
Sites: Bethesda, Maryland
- A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency AnemiaPivotal-lookingRecruiting
AFT Pharmaceuticals, Ltd.Industry
NCT07687784 · 1,366 participants (planned) · Start Nov 2026 · Primary completion Jun 2028
Drug: Ferric Bepectate IV Injection; Ferric Carboxymaltose Injection [Ferinject] and 1 more · For: Iron Deficiency Anemia (IDA)
Sites: Phoenix, Arizona; Coral Gables, Florida; Lake City, Florida · 24 sites in all
- A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)Recruiting
ScinnoHub Pharmaceutical Co., Ltd.Industry
NCT07579949 · 30 participants (planned) · Start Jun 16, 2026 · Primary completion Sep 30, 2027
Drug: SNH-119014 dose 1; SNH-119014 dose 2 and 1 more · For: Thalassemia
Sites: Foshan, China; Guangzhou, China; Maoming, China · 8 sites in all
- The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT06975865 · 192 participants (planned) · Start Aug 12, 2025 · Primary completion Jul 23, 2027
Drug: Rilzabrutinib; Placebo · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Clovis, California · 64 sites in all
- A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)Pivotal-lookingRecruiting
Kind Pharmaceuticals LLCIndustry
NCT07487727 · 240 participants (planned) · Start Dec 3, 2025 · Primary completion Mar 1, 2027
Drug: AND017; ESA · For: Anemia Due to Chronic Kidney Disease
Sites: Beijing, China
- A Phase 3 Evaluation of Sutacimig in Glanzmann ThrombastheniaPivotal-lookingRecruiting
Hemab ApSIndustry
NCT07935356 · 76 participants (planned) · Start Oct 27, 2026 · Primary completion Nov 2029
Drug: Sutacimig · For: Thrombasthenia
Sites: La Jolla, California; Los Angeles, California; Sacramento, California · 9 sites in all
St. Jude Children's Research HospitalAcademic, hospital or other
NCT05583721 · 40 participants (planned) · Start Oct 10, 2023 · Primary completion Sep 2027
Drug: [13N]NH3; Lexiscan · For: Sickle Cell Disease
Sites: Memphis, Tennessee
- A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic AnemiaPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07086976 · 90 participants (planned) · Start Aug 18, 2025 · Primary completion May 31, 2028
Drug: rilzabrutinib; placebo · For: Autoimmune Haemolytic Anaemia
Sites: Phoenix, Arizona; Tucson, Arizona; Duarte, California · 105 sites in all
EuroBloodNet AssociationAcademic, hospital or other
NCT07331818 · 45 participants (planned) · Start Mar 17, 2026 · Primary completion Sep 2028
Drug: Reblozyl · For: Hereditary Red Blood Cell Disorder (Disorder)
Sites: Lille, France; Montpellier, France; Paris, France · 6 sites in all
- Carboplatin or Olaparib for BRcA Deficient Prostate CancerPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT04038502 · 100 participants (planned) · Start Oct 1, 2019 · Primary completion Aug 31, 2027
Drug: Carboplatin; Olaparib · For: Metastatic Castrate Resistant Prostate Cancer; BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2; RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Sites: West Los Angeles, California; Aurora, Colorado; Washington D.C., District of Columbia · 18 sites in all
Disc Medicine, IncIndustry
NCT07187973 · 24 participants (planned) · Start Jan 6, 2026 · Primary completion Jun 2027
Drug: DISC-3405 · For: Sickle Cell Disease
Sites: Birmingham, Alabama; San Francisco, California; Atlanta, Georgia · 11 sites in all
- Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUSPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05795140 · 65 participants (planned) · Start May 8, 2024 · Primary completion Jul 16, 2032
Drug: Iptcaopan 200 mg · For: Atypical Hemolytic Uremic Syndrome
Sites: São Paulo, Brazil; Rio de Janeiro, Brazil; Beijing, China · 10 sites in all
St. Jude Children's Research HospitalAcademic, hospital or other
NCT07616154 · 45 participants (planned) · Start Sep 10, 2026 · Primary completion Sep 2034
Drug: Cyclophosphamide 50mg; Abatacept and 6 more · For: Sickle Cell Disease
Sites: Memphis, Tennessee
University Hospital TuebingenAcademic, hospital or other
NCT07214064 · 27 participants (planned) · Start Feb 19, 2026 · Primary completion Aug 2027
Drug: RIC regimen · For: AML (Acute Myeloid Leukemia); MDS/AML; MDS (Myelodysplastic Syndrome)
Sites: Tübingen, Germany
- Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive CrisisPivotal-lookingRecruiting
Imam Abdulrahman Bin Faisal UniversityAcademic, hospital or other
NCT07188766 · 394 participants (planned) · Start Oct 5, 2025 · Primary completion Aug 2028
Drug: Sodium Chloride (NaCl) 0.9 %; Sodium Chloride (NaCl) 0.9 % · For: SCD; Vaso Occlussive Crisis
Sites: Dammam, Saudi Arabia; Dhahran, Saudi Arabia; Jubail, Saudi Arabia · 5 sites in all
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06439082 · 354 participants (planned) · Start Oct 24, 2024 · Primary completion Jul 2, 2029
Drug: Crizanlizumab; Placebo · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Orange, California; Washington D.C., District of Columbia · 36 sites in all
- Iron Treatment for Iron Deficiency Anemia in Children and Young Adults With Crohn's DiseasePivotal-lookingRecruiting
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT07925450 · 150 participants (planned) · Start Sep 13, 2023 · Primary completion Mar 13, 2029
Drug: Iron (ferrous sulfate) · For: Crohn's Disease; Iron Deficiency Anemia
Sites: New York, New York
- A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood TransfusionsPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07422480 · 300 participants (planned) · Start May 21, 2026 · Primary completion Apr 30, 2029
Drug: Elritercept; Epoetin Alfa · For: Myelodysplastic Syndrome; Anemia
Sites: Gilbert, Arizona; Duarte, California; Santa Rosa, California · 166 sites in all
- A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking RuxolitinibPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07623161 · 324 participants (planned) · Start Sep 10, 2026 · Primary completion Dec 7, 2029
Drug: Placebo; Elritercept · For: Myelofibrosis; Anemia
Sites: Gilbert, Arizona; Glendale, California; Whittier, California · 214 sites in all
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07287228 · 37 participants (planned) · Start Dec 17, 2025 · Primary completion Dec 31, 2027
Drug: Daratumumab · For: Aplastic Anemia; Refractory; Relapse
Sites: Tianjin, China
- A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06499285 · 225 participants (planned) · Start May 6, 2025 · Primary completion Sep 15, 2028
Drug: Elritercept; Placebo · For: Myelodysplastic Syndromes
Sites: Duarte, California; Glendale, California; La Jolla, California · 182 sites in all
- A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it WorksPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05744921 · 202 participants (planned) · Start Mar 7, 2023 · Primary completion Oct 10, 2028
Drug: Pozelimab; Cemdisiran · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Curitiba, Brazil; São Paulo, Brazil; Toronto, Canada · 50 sites in all
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT05904093 · 35 participants (planned) · Start Dec 18, 2024 · Primary completion May 14, 2027
Drug: Fostamatinib · For: Sickle Cell Disorders; Sickle Cell Disease; Hemoglobin S and 2 more
Sites: Bethesda, Maryland
University of PennsylvaniaAcademic, hospital or other
NCT06665997 · 65 participants (planned) · Start Jun 26, 2025 · Primary completion Jul 31, 2028
Drug: Depot medroxyprogesterone acetate (DMPA) · For: Sickle Cell Disease (SCD); Vaso-Occlusive Pain Episode in Sickle Cell Disease
Sites: Atlanta, Georgia; Philadelphia, Pennsylvania
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07752121 · 190 participants (planned) · Start Sep 3, 2026 · Primary completion Aug 31, 2030
Drug: Luspatercept · For: Myelodysplastic Neoplasms
Sites: Mainz, Germany
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.